Cozaar in heart failure

The licence for Cozaar (losartan) has been extended to include the treatment of chronic heart failure.

It is indicated in patients 60 years and over where treatment with ACE inhibitors is contraindicated or not tolerated, especially due to cough. Patients should have a left ventricular ejection fraction greater or equal to 40 per cent and be stabilised with chronic heart failure treatment. Patients with heart failure who have been stabilised with an ACE inhibitor should not be switched to losartan.

The starting dose is 12.5mg daily and can be titrated at weekly intervals to the usual maintenance dose of 50mg daily.

The MHRA have reinstated the black triangle on Cozaar, requesting that intensive monitoring is carried out for the use of Cozaar in heart failure.

View Cozaar drug record

Further information: Merck Sharp & Dohme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...